October 25, 2025 3 min read
Folate is essential for DNA synthesis, neural tube development, and methylation — making adequate intake critical during preconception and early pregnancy, when embryonic cell division is at its most rapid. The form of folate matters: methylfolate (5-MTHF) bypasses the MTHFR conversion step that is impaired in approximately 40% of people.
Folate is required for purine and pyrimidine synthesis — the building blocks of DNA. During the first 28 days after conception, the neural tube forms and closes. Inadequate folate during this critical window increases the risk of neural tube defects (spina bifida, anencephaly) by 50–70%. This is why folate adequacy must be established before conception — by the time most women confirm pregnancy, the neural tube has already closed.
Beyond neural tube prevention, folate supports oocyte quality, endometrial development, and embryo implantation. In men, folate status correlates with sperm DNA integrity and count. Both partners' folate status matters for fertility outcomes.
The FDA mandated folic acid fortification of grain products in 1998, which reduced neural tube defects by 26%. However, folic acid is a synthetic form that must be converted to 5-MTHF through the MTHFR enzyme before the body can use it. Approximately 40% of people carry MTHFR C677T or A1298C variants that reduce this conversion efficiency by 30–70%.
For women planning pregnancy, methylfolate (5-MTHF) is the preferred supplemental form — it's effective regardless of MTHFR status and doesn't carry the risk of unmetabolized folic acid accumulation. Clinical doses for preconception and pregnancy are 400–800mcg of methylfolate daily (some practitioners recommend up to 1,000mcg for women with MTHFR variants or history of neural tube defects).
Essentially-U includes Quatrefolic® — a patented, crystalline form of methylfolate that provides the bioactive form of folate regardless of individual MTHFR genetics.
The intersection of MTHFR variants and pregnancy deserves special attention because the stakes are uniquely high. Women with homozygous C677T variants (approximately 10% of the population) have the most impaired folate metabolism — and the highest neural tube defect risk. Standard prenatal vitamins containing folic acid may not adequately raise functional folate levels in these women, because their MTHFR enzyme cannot efficiently convert folic acid to the usable 5-MTHF form.
Unmetabolized folic acid (UMFA) may also accumulate, and while research on UMFA's health effects is still evolving, it has been associated with reduced natural killer cell activity — a concern during pregnancy when immune modulation is critical for maintaining the pregnancy while protecting against infection.
The solution is straightforward: use methylfolate (5-MTHF) rather than folic acid in prenatal supplements. This bypasses the MTHFR bottleneck entirely, providing the bioactive form regardless of genetic status. Quatrefolic (the form used in Essentially-U) is a patented, crystalline salt of 5-MTHF with documented stability and bioavailability.
While folate receives appropriate attention for neural tube development, choline is increasingly recognized as equally critical — yet rarely included in prenatal supplements at adequate doses. Choline is required for neural tube closure (working alongside folate), brain development (the primary source of phosphatidylcholine for neuronal membranes), and epigenetic programming (choline status during pregnancy affects DNA methylation patterns in the offspring). The adequate intake during pregnancy is 450mg daily, but most women consume less than 350mg through diet alone.
When should I start taking folate before pregnancy?
At least 1–3 months before conception. Folate needs time to build adequate tissue levels, and the neural tube closes by day 28 — often before pregnancy is confirmed. If pregnancy is possible, folate should already be on board.
Can I get enough folate from food?
Dark leafy greens, legumes, and fortified grains provide dietary folate, but supplementation is recommended for all women of childbearing age because the consequences of insufficiency during early pregnancy are severe and the critical window is narrow.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Comments will be approved before showing up.
May 15, 2026 4 min read
Read MoreSign up to get the latest on sales, new releases and more …
Sign up and get the latest on sales, new releases, and more...